An Observational Study Research to Collect the Effectiveness and Safety Data of KUVAN Retrospectively in Chinese Subjects With Hyperphenylalaninemia (HPA) Caused by Tetrahydrobiopterin (BH4) Deficiency
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Sapropterin (Primary)
- Indications Hyperphenylalaninaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms ROSEKA
- Sponsors BioMarin Pharmaceutical
Most Recent Events
- 08 Mar 2019 New trial record